Researcher Nie zongxiu, associate researcher Xiong Caiqiao and collaborators of the Institute of chemistry, Chinese Academy of sciences have made new progress in the field of in situ release mass spectrometry imaging of nano carrier drugs

Mass spectrometry has been widely used in the detection of proteins, sugars, metabolic small molecules in the field of biomedicine due to its advantages of fast, high sensitivity and high throughput Recently, researcher Nie zongxiu and associate researcher Xiong Caiqiao from the Institute of chemistry, Chinese Academy of Sciences, cooperated with scholars from Johns hewkins Medical College in the United States to develop a new type of unlabeled laser desorption ionization mass spectrometry (ldimsi) By monitoring the inherent mass spectrum signal intensity ratio of nano carriers and drug molecules, we have achieved In situ drug release of nano carriers in tissues was quantitatively analyzed by mass spectrometry imaging The results were published in science advanced (DOI: 10.1126 / sciadv Aat9039) Using the LDI MSI technology, we can trace the distribution of nano carriers and drugs in vivo according to the mass spectrum fingerprints of MoS 2 Nano tablets and DOX simultaneously produced by laser ablation This process does not need any label and is not interfered by endogenous molecules The researchers measured the change of the ratio of the peak intensity of the mass spectrum of nano carrier and drug in situ In normal and tumor model mice, the release of drugs in tissues and tissues showed tissue-dependent, the most in tumors, the least in liver The technique of unlabeled laser desorption ionization mass spectrometry (ldimsi) overcomes the shortcomings of the traditional detection methods, such as limited spatial resolution, complex labeling process, and difficult to track nano carriers and drugs at the same time The next step for the researchers is to apply the technology to the in situ drug release study of adriamycin liposome which has entered the clinical stage.